A phase I pharmacokinetic (PK) study of TSU-68 plus S-1 and oxaliplatin (SOX) in patients with metastatic colorectal cancer (mCRC) treated with prior chemotherapy

被引：0
|
作者：
Shin, Sang Joon
Ahn, Joong Bae
Jeung, Hei-Cheul
Rha, Sun Young
Roh, Jae Kyung
Ahn, Jung Ryun
Kim, Chan
Chung, Hyun Cheol
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-09-B8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B8
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase I/II and pharmacokinetic study of combination chemotherapy with S-1 and oxaliplatin in patients with previously untreated metastatic or recurrent gastric cancer
    Park, I.
    Lee, J.
    Ryu, M.
    Chang, H.
    Kim, T.
    Sym, S.
    Lee, S.
    Jang, G.
    Bae, K.
    Kang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer
    Park, Sook Ryun
    Hong, Yong Sang
    Lim, Hyeong-Seok
    Seong, Moon-Woo
    Kong, Sun-Young
    Kim, Sun Young
    Park, Young-Iee
    Jung, Kyung Hae
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (05) : 953 - 964
  • [33] Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer (vol 109, pg 2079, 2013)
    Koizumi, W.
    Yamaguchi, K.
    Hosaka, H.
    Takinishi, Y.
    Nakayama, N.
    Hara, T.
    Muro, K.
    Baba, H.
    Sasaki, Y.
    Nishina, T.
    Fuse, N.
    Esaki, T.
    Takagi, M.
    Gotoh, M.
    Sasaki, T.
    BRITISH JOURNAL OF CANCER, 2014, 111 (12) : 2382 - 2382
  • [34] PHASE II STUDY OF S-1 COMBINED WITH IRINOTECAN AND OXALIPLATIN (TIROX) IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
    Hong, Y. S.
    Kim, S. Y.
    Park, J. W.
    Lim, S.
    Choi, H. S.
    Jeong, S. Y.
    Kim, D. Y.
    Hong, C. W.
    Sohn, D. K.
    Jung, K. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 136 - 136
  • [35] S-1 plus oxaliplatin versus capecitabine plus oxaliplatin chemotherapy in the treatment of patients with metastatic colorectal cancer: A meta-analysis
    Lalusis, J.
    Pandy, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S94 - S94
  • [36] Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/I-LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC).
    Nakamura, Masato
    Yamada, Yasuhide
    Takahari, Daisuke
    Matsumoto, Hiroshi
    Baba, Hideo
    Yoshida, Kazuhiro
    Yoshida, Motoki
    Iwamoto, Shigeyoshi
    Shimada, Ken
    Komatsu, Yoshito
    Sasaki, Yasutsuna
    Satoh, Taroh
    Takahashi, Keiichi
    Mishima, Hideyuki
    Muro, Kei
    Watanabe, Masahiko
    Sakata, Yuh
    Morita, Satoshi
    Shimada, Yasuhiro
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer
    Kemeny, N
    Tong, W
    Gonen, M
    Stockman, J
    Di Lauro, C
    Teitcher, J
    White, P
    Price, C
    Saltz, L
    Sharma, S
    Graham, MA
    ANNALS OF ONCOLOGY, 2002, 13 (09) : 1490 - 1496
  • [38] PHASE II STUDY OF S-1, ORAL LEUCOVORIN, OXALIPLATIN AND BEVACIZUMAB COMBINATION THERAPY (SOL plus BV; SOLA) IN PATIENTS WITH UNRESECTABLE METASTATIC COLORECTAL CANCER (MCRC)
    Miyata, Y.
    Nishina, T.
    Kato, T.
    Yamazaki, K.
    Yoshino, T.
    Esaki, T.
    Moriwaki, T.
    Hyodo, I.
    ANNALS OF ONCOLOGY, 2012, 23 : 131 - 131
  • [39] Phase II study of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination therapy (SOL plus BV; SOLA) in patients with unresectable metastatic colorectal cancer (mCRC).
    Kato, Takeshi
    Nishina, Tomohiro
    Yamazaki, Kentaro
    Yoshino, Takayuki
    Miyata, Yoshinori
    Esaki, Taito
    Moriwaki, Toshikazu
    Hyodo, Ichinosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [40] A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients
    Hsu, Hung-Chih
    Chou, Wen-Chi
    Kuan, Feng-Che
    Lee, Kuan-Der
    Rau, Kun-Ming
    Huang, En-Seng
    Yang, Tsai-Sheng
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 6061 - 6070
12345